Secukinumab treatment in psoriasis patients with liver condition
Part of Digestive system, Hormones & metabolism, Skin clinical trials.
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriasis (with or without psoriatic arthritis) and a liver condition called MASLD.
- You started taking secukinumab between January 2021 and December 2023.
- You are 18 years or older at the time you started the drug.
- Secukinumab is your first, second, or third biologic treatment for psoriasis.
- You have at least one risk factor for heart or metabolic problems, like high blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study tests whether adding metformin (a diabetes medicine) to secukinumab (a biologic injection) works better for people with moderate-to-severe plaque psoriasis who are overweight or obese. It might help control psoriasis and reduce inflammation.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study is testing how well a new medication called Xeligekimab works in real-life settings for people with moderate to severe plaque psoriasis. It may help if you are starting this treatment for the first time and want to contribute to learning more about its effects.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This study looks at how different ways of taking secukinumab (Cosentyx) over the long term affect skin clearance in people with moderate-to-severe psoriasis. It tries to find which dosing schedule keeps skin clear best over time.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.